PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 27256586-5 2016 Tigecycline resistance has been reported in some studies to be elevated among extended-spectrum beta-lactamase (ESBL)-producing, MDR, extensively drug-resistant and CR isolates. Tigecycline 0-11 EsbL Escherichia coli 78-110 26687647-0 2016 Antibiotic drug tigecycline reduces neuroblastoma cells proliferation by inhibiting Akt activation in vitro and in vivo. Tigecycline 16-27 AKT serine/threonine kinase 1 Homo sapiens 84-87 26687647-4 2016 Furthermore, it was found that tigecycline induced G1-phase cell cycle arrest instead of apoptosis by means of Akt pathway inhibition. Tigecycline 31-42 AKT serine/threonine kinase 1 Homo sapiens 111-114 26687647-5 2016 In neuroblastoma cell lines, the Akt activator insulin-like growth factor-1 (hereafter referred to as IGF-1) reversed tigecycline-induced cell cycle arrest. Tigecycline 118-129 AKT serine/threonine kinase 1 Homo sapiens 33-36 26687647-5 2016 In neuroblastoma cell lines, the Akt activator insulin-like growth factor-1 (hereafter referred to as IGF-1) reversed tigecycline-induced cell cycle arrest. Tigecycline 118-129 insulin like growth factor 1 Homo sapiens 47-75 26687647-5 2016 In neuroblastoma cell lines, the Akt activator insulin-like growth factor-1 (hereafter referred to as IGF-1) reversed tigecycline-induced cell cycle arrest. Tigecycline 118-129 insulin like growth factor 1 Homo sapiens 102-107 26687647-7 2016 After tigecycline treatment in vivo, the Akt pathway inhibition was confirmed as well. Tigecycline 6-17 AKT serine/threonine kinase 1 Homo sapiens 41-44 26687647-8 2016 Collectively, our data provided strong evidences that tigecycline inhibited neuroblastoma cells growth and proliferation through the Akt pathway inhibition in vitro and in vivo. Tigecycline 54-65 AKT serine/threonine kinase 1 Homo sapiens 133-136 26513341-7 2016 Apart from cephalosporins, ESBL-producing strains were also less likely to be susceptible to other antibiotics, such as quinolones, gentamicin, netilmicin, and cotrimoxazole, more than 90% of which were still susceptible to amikacin, carbapenems, colistin, and tigecycline. Tigecycline 261-272 EsbL Escherichia coli 27-31 26427870-0 2015 Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by inhibiting Wnt/beta-catenin signaling. Tigecycline 39-50 catenin beta 1 Homo sapiens 110-122 26823491-0 2016 Tigecycline Inhibits Glioma Growth by Regulating miRNA-199b-5p-HES1-AKT Pathway. Tigecycline 0-11 hes family bHLH transcription factor 1 Homo sapiens 63-67 26823491-0 2016 Tigecycline Inhibits Glioma Growth by Regulating miRNA-199b-5p-HES1-AKT Pathway. Tigecycline 0-11 AKT serine/threonine kinase 1 Homo sapiens 68-71 26823491-5 2016 We found that miR-199b-5p expression was significantly increased after tigecycline treatment, and miR-199b-5p target gene HES1 was downregulated. Tigecycline 71-82 hes family bHLH transcription factor 1 Homo sapiens 122-126 26823491-9 2016 These results suggest that tigecycline may induce cell-cycle arrest and inhibit glioma growth by regulating miRNA-199b-5p-HES1-AKT pathway. Tigecycline 27-38 hes family bHLH transcription factor 1 Homo sapiens 122-126 26823491-9 2016 These results suggest that tigecycline may induce cell-cycle arrest and inhibit glioma growth by regulating miRNA-199b-5p-HES1-AKT pathway. Tigecycline 27-38 AKT serine/threonine kinase 1 Homo sapiens 127-130 26621850-0 2016 Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1/Waf1-dependent manner. Tigecycline 16-27 cyclin dependent kinase inhibitor 1A Homo sapiens 78-85 26621850-0 2016 Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1/Waf1-dependent manner. Tigecycline 16-27 cyclin dependent kinase inhibitor 1A Homo sapiens 86-90 26621850-9 2016 We found that p21 overexpression significantly rescued tigecycline-induced cell proliferation inhibition as well as migration and invasion suppression. Tigecycline 55-66 cyclin dependent kinase inhibitor 1A Homo sapiens 14-17 26621850-10 2016 Taken together, our results revealed that the essential role of p21 in the inhibitory effect of tigecycline on proliferation, migration and invasion of melanoma. Tigecycline 96-107 cyclin dependent kinase inhibitor 1A Homo sapiens 64-67 26427870-2 2015 We show that tigecycline, a FDA-approved antibiotic drug, targets cervical squamous cell carcinoma through inhibiting Wnt/beta-catenin signaling pathway. Tigecycline 13-24 catenin beta 1 Homo sapiens 122-134 26427870-6 2015 We further show that tigecycline decreases level of both cytoplasmic and nuclear beta-catenin and suppressed Wnt/beta-catenin-mediated transcription through increasing levels of Axin 1 in Hela cells. Tigecycline 21-32 catenin beta 1 Homo sapiens 81-93 26427870-6 2015 We further show that tigecycline decreases level of both cytoplasmic and nuclear beta-catenin and suppressed Wnt/beta-catenin-mediated transcription through increasing levels of Axin 1 in Hela cells. Tigecycline 21-32 catenin beta 1 Homo sapiens 113-125 26427870-6 2015 We further show that tigecycline decreases level of both cytoplasmic and nuclear beta-catenin and suppressed Wnt/beta-catenin-mediated transcription through increasing levels of Axin 1 in Hela cells. Tigecycline 21-32 axin 1 Homo sapiens 178-184 26427870-7 2015 In addition, stabilization or overexpression of beta-catenin using pharmacological and genetic approaches abolished the effects of tigecycline in inhibiting proliferation and inducing apoptosis of Hela cells. Tigecycline 131-142 catenin beta 1 Homo sapiens 48-60 26100707-6 2015 Tigecycline inhibited the growth of all of the tested STEC isolates and also inhibited the production of Stxs (Stx2 in particular). Tigecycline 0-11 syntaxin-2 Chlorocebus sabaeus 111-115 26100707-7 2015 In combination with neutralizing antibodies to Stx1 and Stx2, the tigecycline-antibody treatment fully protected Vero cells from Stx toxicity, even when the STEC bacteria and the Vero cells were cultured together. Tigecycline 66-77 syntaxin-2 Chlorocebus sabaeus 56-60 24529941-7 2014 Susceptibility of ESBL screen-positive E. coli and K. pneumoniae was 100.0/97.9% for tigecycline and 99.2/56.1% for meropenem, respectively. Tigecycline 85-96 EsbL Escherichia coli 18-22 25547356-0 2015 Tigecycline treatment causes a decrease in fibrinogen levels. Tigecycline 0-11 fibrinogen beta chain Homo sapiens 43-53 25547356-1 2015 The objective of this study was to assess the impact of tigecycline treatment on coagulation parameters, specifically fibrinogen, in patients with severe infections. Tigecycline 56-67 fibrinogen beta chain Homo sapiens 118-128 25547356-4 2015 Fibrinogen (FIB) levels decreased significantly after the use of tigecycline and normalized after the cessation of treatment. Tigecycline 65-76 fibrinogen beta chain Homo sapiens 0-10 25547356-4 2015 Fibrinogen (FIB) levels decreased significantly after the use of tigecycline and normalized after the cessation of treatment. Tigecycline 65-76 fibrinogen beta chain Homo sapiens 12-15 25547356-8 2015 Prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT) were prolonged after tigecycline use. Tigecycline 113-124 coagulation factor II, thrombin Homo sapiens 0-11 25547356-8 2015 Prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT) were prolonged after tigecycline use. Tigecycline 113-124 coagulation factor II, thrombin Homo sapiens 3-11 25547356-11 2015 The use of tigecycline was associated with decreased FIB levels, which returned to normal after the cessation of treatment. Tigecycline 11-22 fibrinogen beta chain Homo sapiens 53-56 25951751-8 2015 We suggest that patients treated with tigecycline should be monitored for changes in INR, aPTT, and fibrinogen levels to avoid severe, life-threatening coagulation disturbances. Tigecycline 38-49 fibrinogen beta chain Homo sapiens 100-110 24328852-2 2014 These multidrug-resistant isolates, which belonged to a single clone, remained only susceptible to tigecycline, minocycline, and colistin and produced the carbapenem-hydrolyzing oxacillinase, OXA-23. Tigecycline 99-110 class D beta-lactamase OXA-23 Acinetobacter baumannii 192-198 25801560-0 2015 In vitro activity of polymyxin B plus imipenem, meropenem, or tigecycline against KPC-2-producing Enterobacteriaceae with high MICs for these antimicrobials. Tigecycline 62-73 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 82-87 24647004-7 2014 OXA-1 beta-lactamase producing strains were found to be resistant to piperacillin/tazobactam(100%), levofloxacin (91.6%), amikacin (75%), cefoxitin (50%), ertapenem (25%), imipenem (16.6%) and meropenem (16.6%); all were susceptible to tigecycline. Tigecycline 236-247 beta-lactamase OXA-1 Klebsiella pneumoniae 0-5 24647004-10 2014 MD simulation results clearly confirmed the notable loss in stability for tigecycline-blaOXA-1 complex. Tigecycline 74-85 beta-lactamase Klebsiella pneumoniae 86-94 23200736-5 2013 The results showed that tigecycline significantly attenuated the expression and the release of nuclear factor-kappa beta (NF-kappaB), tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), as well as nitric oxide (NO) levels in LPS-induced PC12 cells. Tigecycline 24-35 tumor necrosis factor Rattus norvegicus 134-161 24421836-2 2013 Although limited in their indications, fosfomycin and tigecycline are potential agents to treat infections due to ESBL-producing organisms. Tigecycline 54-65 EsbL Escherichia coli 114-118 24421836-8 2013 CONCLUSION: Although resistance to these antibiotics has previously been reported, the present study confirmed that isolates of ESBL-producing E coli from the Interior Health Region of British Columbia remain highly susceptible to both tigecycline and fosfomycin. Tigecycline 236-247 EsbL Escherichia coli 128-132 23726147-0 2013 In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains. Tigecycline 86-97 OXA-48 Klebsiella pneumoniae 106-112 23726147-3 2013 The aim of this study was to evaluate the in vitro synergistic activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA-48 producing K. pneumoniae strains. Tigecycline 140-151 OXA-48 Klebsiella pneumoniae 160-166 23200736-5 2013 The results showed that tigecycline significantly attenuated the expression and the release of nuclear factor-kappa beta (NF-kappaB), tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), as well as nitric oxide (NO) levels in LPS-induced PC12 cells. Tigecycline 24-35 tumor necrosis factor Rattus norvegicus 163-172 23200736-5 2013 The results showed that tigecycline significantly attenuated the expression and the release of nuclear factor-kappa beta (NF-kappaB), tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), as well as nitric oxide (NO) levels in LPS-induced PC12 cells. Tigecycline 24-35 interleukin 1 beta Rattus norvegicus 178-195 23200736-5 2013 The results showed that tigecycline significantly attenuated the expression and the release of nuclear factor-kappa beta (NF-kappaB), tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), as well as nitric oxide (NO) levels in LPS-induced PC12 cells. Tigecycline 24-35 interleukin 1 beta Rattus norvegicus 197-205 23200736-6 2013 In addition, tigecycline dose-dependently decreased cytochrome c release and caspase-3 activity. Tigecycline 13-24 caspase 3 Rattus norvegicus 77-86 22897076-1 2012 Tigecycline (formerly CAR-936, Tygacyl) is the first glycylcycline antibiotic available for clinical use. Tigecycline 0-11 CXADR pseudogene 1 Homo sapiens 22-25 23114764-0 2013 Tigecycline displays in vivo bactericidal activity against extended-spectrum-beta-lactamase-producing Enterobacteriaceae after 72-hour exposure period. Tigecycline 0-11 EsbL Escherichia coli 59-91 23114764-1 2013 Progressively enhanced activity of a humanized tigecycline (TGC) regimen was noted over 3 days against an extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli isolate and an ESBL-producing Klebsiella pneumoniae isolate. Tigecycline 47-58 EsbL Escherichia coli 106-138 23114764-1 2013 Progressively enhanced activity of a humanized tigecycline (TGC) regimen was noted over 3 days against an extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli isolate and an ESBL-producing Klebsiella pneumoniae isolate. Tigecycline 60-63 EsbL Escherichia coli 106-138 23198452-7 2012 Tigecycline and colistin maintained excellent activity against most ESBL and carbapenem resistant bacteria relevant to the treatment by these agents. Tigecycline 0-11 EsbL Escherichia coli 68-72 22796889-9 2012 All MBL producers were susceptible to colistin and tigecycline. Tigecycline 51-62 NDM-1 Citrobacter freundii 4-7 20512088-5 2010 Tigecycline had good activity against most ESBL-producing Enterobacteriaceae and may be a therapeutic alternative to carbapenems in some infections caused by ESBL-producing isolates, many of which are also multiresistant to quinolones, aminoglycosides, and classical tetracyclines. Tigecycline 0-11 EsbL Klebsiella oxytoca 43-47 22832033-8 2012 Antimicrobial susceptibility testing of selected, molecularly characterized ESBL producers revealed susceptibility to tigecycline among 97.9% (191/195) of the E. coli and 78.8% (26/33) of the K. pneumoniae isolates. Tigecycline 118-129 EsbL Escherichia coli 76-80 22010205-5 2012 RESULTS: Exposure of the cells to fMLP resulted in activation of the generation of ROS, as well as release of the granule proteases, all of which were significantly increased by pre-incubation of the cells with tigecycline in a dose-dependent manner. Tigecycline 211-222 formyl peptide receptor 1 Homo sapiens 34-38 22065244-0 2012 Tigecycline accelerates staphylococcal-infected burn wound healing through matrix metalloproteinase-9 modulation. Tigecycline 0-11 matrix metallopeptidase 9 Rattus norvegicus 75-101 22065244-11 2012 Infected rats treated with tigecycline showed a significant decrease in MMP-9 expression both in epithelium and in dermis compared with rats treated with teicoplanin. Tigecycline 27-38 matrix metallopeptidase 9 Rattus norvegicus 72-77 22065244-12 2012 CONCLUSIONS: Tigecycline, besides its antimicrobial activity, exerts an important modulatory effect on MMP-9, accelerating wound healing in staphylococcal-infected burns. Tigecycline 13-24 matrix metallopeptidase 9 Rattus norvegicus 103-108 21976769-10 2011 All hVISA isolates were susceptible to linezolid, tigecycline, and ceftaroline. Tigecycline 50-61 mitochondrial antiviral signaling protein Homo sapiens 4-9 21835972-10 2011 KPC-2- or IMP-producing E. coli transconjugants exhibited reduced susceptibility to carbapenems but were susceptible to polymyxin B and tigecycline with an MIC range of 0.5-2 microg ml(-1), 0.25-2 microg ml(-1), 0.5-4 microg ml(-1), 0.5 microg ml(-1) and 0.5-1 microg ml(-1). Tigecycline 136-147 KPC-2 Escherichia coli 0-5 22094260-4 2011 ShRNA-mediated knockdown of EF-Tu mitochondrial translation factor in leukemic cells reproduced the antileukemia activity of tigecycline. Tigecycline 125-136 Tu translation elongation factor, mitochondrial Homo sapiens 28-33 22196060-9 2011 Of the 22 isolates of E. coli with extended-spectrum beta-lactamase (ESBL), the most susceptible antimicrobial agent were colistin (20/22, 91%), ertapenem (21/22, 96%), meropenem and tigecycline (22/22, 100%). Tigecycline 183-194 EsbL Escherichia coli 35-67 21846669-0 2011 Breakthrough bacteraemia due to tigecycline-resistant Escherichia coli with New Delhi metallo-beta-lactamase (NDM)-1 successfully treated with colistin in a patient with calciphylaxis. Tigecycline 32-43 New Delhi metallo-beta-lactamase Escherichia coli 76-108 21325253-1 2011 This study evaluated the activity of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli co-producing extended-spectrum beta-lactamases and acquired AmpC beta-lactamases. Tigecycline 37-48 beta-lactamase Escherichia coli 253-257 22016687-5 2011 The KPC-2-producing isolate was resistant to all tested beta-lactams (including imipenem and meropenem), amikacin, tobramycin, ciprofloxacin, levofloxacin, and trimethoprim-sulfamethoxazole, but was susceptible to gentamicin, colistin, polymyxin B, and tigecycline. Tigecycline 253-264 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 4-9 21958147-12 2011 Macrolides were very active against isolates of the MAC complex, while tigecycline had excellent activity in vitro against RGM. Tigecycline 71-82 repulsive guidance molecule BMP co-receptor a Homo sapiens 123-126 21685488-11 2011 Overall mortality was higher with tigecycline compared with other regimens [RR 1.29, 95% confidence interval (CI) 1.02-1.64, without heterogeneity]. Tigecycline 34-45 ribonucleotide reductase catalytic subunit M1 Homo sapiens 76-80 21685488-13 2011 Clinical failure was significantly higher with tigecycline (RR 1.16, 95% CI 1.06-1.27) and non-statistically significant higher rates of microbiological failure were demonstrated (RR 1.13, 95% CI 0.99-1.30). Tigecycline 47-58 ribonucleotide reductase catalytic subunit M1 Homo sapiens 60-64 21482488-10 2011 This relatively high prevalence of tigecycline and colistin-resistant isolates indicates an emerging therapeutic problem which may severely compromise the treatment of MDR Acinetobacter spp. Tigecycline 35-46 histocompatibility minor 13 Homo sapiens 186-189 21304190-10 2011 All ESBL and metallo-beta-lactamase producers were resistant to multiple classes of antimicrobials, the latter being sensitive only to colistin and tigecycline. Tigecycline 148-159 beta-lactamase Staphylococcus aureus 21-35 20818104-9 2010 In vitro, all ESBL producers were sensitive to tigecycline. Tigecycline 47-58 EsbL Escherichia coli 14-18 20818104-12 2010 Tigecycline is active against all the ESBL or multidrug resistant (MDR) E. coli and Klebsiella spp. Tigecycline 0-11 EsbL Escherichia coli 38-42 20697161-5 2010 We describe a carbapenemase-producing K pneumoniae evolving resistance to tigecycline in a 75-year-old male after a prolonged stay in a critical care unit. Tigecycline 74-85 OXA-48 Klebsiella pneumoniae 14-27 23214282-15 2012 The effectiveness of tigecycline against ESBL-producing E. coli strains was similar to that of imipenem and meropenem. Tigecycline 21-32 EsbL Escherichia coli 41-45 22155819-5 2012 The MIC(90) values of tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 mug/ml, respectively. Tigecycline 22-33 EsbL Escherichia coli 53-57 22155819-5 2012 The MIC(90) values of tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 mug/ml, respectively. Tigecycline 22-33 EsbL Escherichia coli 77-81 22155819-9 2012 For routine susceptibility testing of ESBL-producing K. pneumoniae and A. baumannii against tigecycline, the broth microdilution method should be used because of the poor correlation of results between these two methods. Tigecycline 92-103 EsbL Escherichia coli 38-42 22203598-4 2012 Among the Gram-negative bacteria, the tigecycline susceptibility rates were 99.65% for ESBL-producing E. coli (MIC(90), 0.5 mug/ml) and 96.32% for ESBL-producing K. pneumoniae (MIC(90), 2 mug/ml) when interpreted by FDA criteria but were 98.7% and 85.8%, respectively, when interpreted by EUCAST-2011 criteria. Tigecycline 38-49 EsbL Escherichia coli 87-91 22203598-4 2012 Among the Gram-negative bacteria, the tigecycline susceptibility rates were 99.65% for ESBL-producing E. coli (MIC(90), 0.5 mug/ml) and 96.32% for ESBL-producing K. pneumoniae (MIC(90), 2 mug/ml) when interpreted by FDA criteria but were 98.7% and 85.8%, respectively, when interpreted by EUCAST-2011 criteria. Tigecycline 38-49 EsbL Escherichia coli 147-151 20846813-0 2010 Salvage therapy with tigecycline for recurrent infection caused by ertapenem-resistant extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Tigecycline 21-32 beta-lactamase Klebsiella pneumoniae 105-119 20727474-0 2010 In vitro activity of tigecycline and comparators on Acinetobacter spp. Tigecycline 21-32 histocompatibility minor 13 Homo sapiens 66-69 20031463-0 2010 The susceptibility to tigecycline of Acinetobacter spp. Tigecycline 22-33 histocompatibility minor 13 Homo sapiens 51-54 20512088-5 2010 Tigecycline had good activity against most ESBL-producing Enterobacteriaceae and may be a therapeutic alternative to carbapenems in some infections caused by ESBL-producing isolates, many of which are also multiresistant to quinolones, aminoglycosides, and classical tetracyclines. Tigecycline 0-11 EsbL Klebsiella oxytoca 158-162 20192819-5 2010 bla(CTX-M)-carrying isolates were 95.5 and 98.5%, susceptible to Imipenem and meropenem respectively, and were all susceptible to tigecycline, whereas KPC-producing isolates were highly resistant to all antimicrobials tested except polymyxin B and tigecycline (90.6% and 99.4% susceptibility, respectively). Tigecycline 130-141 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 4-7 20045291-0 2010 Activity of tigecycline against multidrug-resistant clinical isolates of Clostridium spp. Tigecycline 12-23 histocompatibility minor 13 Homo sapiens 85-88 20192819-5 2010 bla(CTX-M)-carrying isolates were 95.5 and 98.5%, susceptible to Imipenem and meropenem respectively, and were all susceptible to tigecycline, whereas KPC-producing isolates were highly resistant to all antimicrobials tested except polymyxin B and tigecycline (90.6% and 99.4% susceptibility, respectively). Tigecycline 248-259 cytochrome P450 family 27 subfamily A member 1 Homo sapiens 4-7 18782779-0 2008 Susceptibility testing of tigecycline against Acinetobacter spp. Tigecycline 26-37 histocompatibility minor 13 Homo sapiens 60-63 19451133-0 2009 Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp. Tigecycline 40-51 histocompatibility minor 13 Homo sapiens 130-133 19451133-1 2009 OBJECTIVES: To compare the tigecycline activity profile against Acinetobacter spp. Tigecycline 27-38 histocompatibility minor 13 Homo sapiens 78-81 19015360-2 2009 This study was designed to identify, at the sequence level, the genes responsible for the extended-spectrum-beta-lactamase (ESBL) phenotypes of Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during the global tigecycline phase 3 clinical trials. Tigecycline 244-255 EsbL Escherichia coli 90-122 19297274-7 2009 Our results suggest that tigecycline may be an acceptable alternative for therapy in patients with VAP caused by MDR-Acinetobacter spp. Tigecycline 25-36 histocompatibility minor 13 Homo sapiens 131-134 20551633-14 2010 CONCLUSIONS: Tigecycline breakpoints for Acinetobacter spp. Tigecycline 13-24 histocompatibility minor 13 Homo sapiens 55-58 19364850-1 2009 Tigecycline is a glycylcycline with activity against Enterobacteriaceae, including multidrug-resistant isolates of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta-lactamase (ESBL) and carbapenemases. Tigecycline 0-11 EsbL Escherichia coli 168-200 19364850-1 2009 Tigecycline is a glycylcycline with activity against Enterobacteriaceae, including multidrug-resistant isolates of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta-lactamase (ESBL) and carbapenemases. Tigecycline 0-11 EsbL Escherichia coli 202-206 19095416-7 2009 In vitro studies reveal that tigecycline and colistin are the only antibacterial agents with consistent activity against MBL-producing strains. Tigecycline 29-40 mannose-binding lectin family member 3, pseudogene Homo sapiens 121-124 18802728-3 2009 The aim of this study was to assess the in vitro activity of tigecycline against ESBL-producing Escherichia coli, ESBL-producing Klebsiella spp., and multidrug-resistant Enterobacter spp. Tigecycline 61-72 EsbL Escherichia coli 81-85 18802728-3 2009 The aim of this study was to assess the in vitro activity of tigecycline against ESBL-producing Escherichia coli, ESBL-producing Klebsiella spp., and multidrug-resistant Enterobacter spp. Tigecycline 61-72 EsbL Escherichia coli 114-118 19013351-0 2008 Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae. Tigecycline 62-73 CTX-M-15 Klebsiella pneumoniae 103-135 19013351-4 2008 Tigecycline had excellent in-vitro activity against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (N = 275) with MIC(90) 0.5 microg/mL and a 99.6% susceptibility rate, and also against ESBL-producing Klebsiella pneumoniae (N = 324) with MIC(90) 2 microg/mL and a 98.5% susceptibility rate. Tigecycline 0-11 EsbL Escherichia coli 52-84 19013351-4 2008 Tigecycline had excellent in-vitro activity against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (N = 275) with MIC(90) 0.5 microg/mL and a 99.6% susceptibility rate, and also against ESBL-producing Klebsiella pneumoniae (N = 324) with MIC(90) 2 microg/mL and a 98.5% susceptibility rate. Tigecycline 0-11 EsbL Escherichia coli 86-90 19013351-4 2008 Tigecycline had excellent in-vitro activity against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (N = 275) with MIC(90) 0.5 microg/mL and a 99.6% susceptibility rate, and also against ESBL-producing Klebsiella pneumoniae (N = 324) with MIC(90) 2 microg/mL and a 98.5% susceptibility rate. Tigecycline 0-11 EsbL Escherichia coli 206-210 19013351-7 2008 Limited agreement (<80%) was found between the broth microdilution and the Etest methods when determining the in-vitro activity of tigecycline against ESBL- producing K. pneumoniae and K. oxytoca. Tigecycline 134-145 CTX-M-15 Klebsiella pneumoniae 154-158 18676620-5 2008 Tigecycline was active against more than 99% of 1936 Escherichia coli isolates characterized by any of the above resistance patterns (including 1636 ESBL-producing isolates) using the US Food and Drug Administration (FDA) breakpoint of susceptibility (MIC < or = 2 mg/L). Tigecycline 0-11 EsbL Escherichia coli 149-153 18567913-0 2008 Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp. Tigecycline 44-55 histocompatibility minor 13 Homo sapiens 104-107 18614749-2 2008 Tigecycline has in vitro activity against Acinetobacter spp. Tigecycline 0-11 histocompatibility minor 13 Homo sapiens 56-59 18614749-4 2008 OBJECTIVE: To describe the clinical and microbiologic outcomes of patients who received tigecycline for the treatment of infections caused by Acinetobacter spp. Tigecycline 88-99 histocompatibility minor 13 Homo sapiens 156-159 18676620-11 2008 In clinical studies, 69.7% of the 33 reported patients treated with tigecycline achieved resolution of an infection caused by a carbapenem-resistant or ESBL-producing or MDR Enterobacteriaceae. Tigecycline 68-79 EsbL Escherichia coli 152-156 18676620-12 2008 CONCLUSIONS: Tigecycline is microbiologically active against almost all of the ESBL or MDR E. coli isolates and the great majority of ESBL or MDR Klebsiella spp. Tigecycline 13-24 EsbL Escherichia coli 79-83 18676620-12 2008 CONCLUSIONS: Tigecycline is microbiologically active against almost all of the ESBL or MDR E. coli isolates and the great majority of ESBL or MDR Klebsiella spp. Tigecycline 13-24 EsbL Escherichia coli 134-138 18689874-0 2008 Comment on: Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp. Tigecycline 56-67 histocompatibility minor 13 Homo sapiens 116-119 18787741-0 2008 In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae. Tigecycline 21-32 CTX-M-15 Klebsiella pneumoniae 62-94 18787741-2 2008 In this study, we evaluated the in vitro antimicrobial activity of tigecycline against ESBL-producing Enterobacteriaceae, including Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae. Tigecycline 67-78 CTX-M-15 Klebsiella pneumoniae 87-91 18787741-4 2008 The in vitro activity of tigecycline against these ESBL producers was tested by use of Etest strips. Tigecycline 25-36 CTX-M-15 Klebsiella pneumoniae 51-55 18787741-6 2008 CONCLUSIONS: Tigecycline, a new semisynthetic glycylcycline, may be considered an alternative drug of choice for patients infected with ESBL-producing bacteria. Tigecycline 13-24 CTX-M-15 Klebsiella pneumoniae 136-140 18077630-0 2008 Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Tigecycline 15-26 beta-lactamase Escherichia coli 78-92 17996417-1 2008 We report the use of tigecycline, firstly with colistin and finally alone, in a patient with a persistent breakthrough bacteremia due to a Klebsiella pneumoniae isolate harboring a metallo-beta-lactamase (VIM-1) and an extended-spectrum beta-lactamase (SHV-12). Tigecycline 21-32 beta-lactamase Klebsiella pneumoniae 189-203 17996417-1 2008 We report the use of tigecycline, firstly with colistin and finally alone, in a patient with a persistent breakthrough bacteremia due to a Klebsiella pneumoniae isolate harboring a metallo-beta-lactamase (VIM-1) and an extended-spectrum beta-lactamase (SHV-12). Tigecycline 21-32 beta-lactamase Klebsiella pneumoniae 237-251 16870760-12 2006 Tigecycline, lacking cross-resistance with other compounds, could represent an opportunity to reduce the intensity of selection for ESBL-producing organisms derived from the use of other antimicrobial agents. Tigecycline 0-11 CTX-M-15 Klebsiella pneumoniae 132-136 18154548-2 2008 The activity and potential use of two old antimicrobials, nitrofurantoin and fosfomycin, and the new compound tigecycline for treatment of infections due to ESBL-producing Enterobacteriaceae, with special emphasis on E. coli, are reviewed. Tigecycline 110-121 EsbL Escherichia coli 157-161 18154548-12 2008 Finally, for treatment of systemic infections in the hospital setting, tigecycline could be an option that would reduce selection for ESBL-producing organisms. Tigecycline 71-82 EsbL Escherichia coli 134-138 17548459-0 2007 Tigecycline disk diffusion breakpoints of Acinetobacter spp. Tigecycline 0-11 histocompatibility minor 13 Homo sapiens 56-59 17662552-1 2007 Time-kill kinetics performed with tigecycline, in fresh MHB, demonstrated a consistent 1 to 2 log(10) CFU/ml reduction in bacterial counts against the majority of clinically relevant pathogens tested. Tigecycline 34-45 MHB Homo sapiens 56-59 17462865-0 2007 In vitro antibacterial activity of tigecycline in comparison with doxycycline, ciprofloxacin and rifampicin against Brucella spp. Tigecycline 35-46 histocompatibility minor 13 Homo sapiens 125-128 17045785-0 2006 Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum beta-lactamase-producing Escherichia coli in Granada, Spain. Tigecycline 12-23 beta-lactamase Staphylococcus aureus 97-111 17045785-1 2006 We evaluated the in vitro activity of tigecycline using the Etest and disk diffusion method according to Clinical and Laboratory Standards Institute guidelines against clinical isolates of methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA) as well as for CTX-M-9 extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and SHV ESBL-producing E. coli. Tigecycline 38-49 beta-lactamase Staphylococcus aureus 326-340 17012300-12 2006 On average, the systemic exposure of tigecycline in bone, SF and CSF ranged from 11% to 41% of serum concentrations. Tigecycline 37-48 colony stimulating factor 2 Homo sapiens 65-68 34816103-6 2021 In vivo, the combination of tigecycline and cytarabine reduced leukemia progression in the AML-PDX model with high CDK6-AS1 levels, supporting the concept of a mitochondrial vulnerability. Tigecycline 28-39 cyclin dependent kinase 6 Homo sapiens 115-119 16286361-4 2005 RESULTS: MICs of tigecycline in fresh MHB were up to two doubling dilutions higher than on or in MHA, ISA or ISB. Tigecycline 17-28 annexin A13 Homo sapiens 102-105 12604529-14 2003 The MICs of the narrower-spectrum semisynthetic tetracyclines doxycycline and minocycline increased more substantially than did those of tigecycline and other glycylcyclines against the MexAB-OprM- and MexCD-OprJ-overexpressing mutant strains. Tigecycline 137-148 outer membrane protein OprM Pseudomonas aeruginosa PAO1 192-196 34694885-5 2022 Introducing the ramAp and the truncated ISEcp1 into E. coli have resulted in elevated expression of efflux pump genes and elevated MICs to chloramphenicol, azithromycin, nalidixic acid, ciprofloxacin, sulfamethoxazole, trimethoprim, tetracycline, and tigecycline. Tigecycline 251-262 ISEcp1 Escherichia coli 40-46 16105561-4 2005 Tigecycline inhibited extended-spectrum beta-lactamase and AmpC phenotypes at MIC90 values (minimum inhibitory concentration) of < or =2 microg/mL. Tigecycline 0-11 beta-lactamase Staphylococcus aureus 40-54 16105565-14 2005 Tigecycline was also active against Acinetobacter spp. Tigecycline 0-11 histocompatibility minor 13 Homo sapiens 50-53 34524633-10 2021 On the other hand, OXA-23-like isolates were more sensitive to the combination of tigecycline and colistin. Tigecycline 82-93 class D beta-lactamase OXA-23 Acinetobacter baumannii 19-25 33739229-5 2021 Comparative analysis of 147 Kp genomes and 39 completely assembled chromosomes revealed extensive interruption of acrR by ISKpn26 in all Kp carbapenemase-2 (KPC-2)-producing ST11 Kp isolates, leading to activation of the AcrAB-Tolc multidrug efflux pump and a subsequent reduction in susceptibility to the last-resort antibiotic tigecycline and six other antibiotics. Tigecycline 329-340 Pancreatic endocrine tumor suppressor Homo sapiens 174-178 34816103-6 2021 In vivo, the combination of tigecycline and cytarabine reduced leukemia progression in the AML-PDX model with high CDK6-AS1 levels, supporting the concept of a mitochondrial vulnerability. Tigecycline 28-39 prostaglandin D2 receptor Homo sapiens 120-123 34682825-4 2021 Therefore, the aim of this study is to examine the time course of fibrinogen level changes during tigecycline therapy in critically ill patients. Tigecycline 98-109 fibrinogen beta chain Homo sapiens 66-76 34682825-8 2021 Patients with a greater fibrinogen decrease received a higher dose, a longer treatment and more dose changes of tigecycline, respectively. Tigecycline 112-123 fibrinogen beta chain Homo sapiens 24-34 34161789-1 2021 BACKGROUND: Although in vitro data suggests tigecycline to be active against carbapenemase-producing Klebsiella pneumoniae (KPC), experimental and clinical data are limited. Tigecycline 44-55 OXA-48 Klebsiella pneumoniae 77-90 34236301-0 2021 A stop-gain mutation in sigma factor SigH (MAB_3543c) may be associated with tigecycline resistance in Mycobacteroides abscessus. Tigecycline 77-88 MAB_3543c Mycobacterium abscessus 43-52 34236301-11 2021 The MAB_3543c mutation may represent a novel determinant of tigecycline resistance in M. abscessus. Tigecycline 60-71 MAB_3543c Mycobacterium abscessus 4-13 35572689-0 2022 Emergence of a Hypervirulent Tigecycline-Resistant Klebsiella pneumoniae Strain Co-producing bla NDM-1 and bla KPC-2 With an Uncommon Sequence Type ST464 in Southwestern China. Tigecycline 29-40 TEM beta-lactamase Klebsiella pneumoniae 93-96 35364753-8 2022 The RORs and the 95% confidence intervals (95% CI) of tigecycline, minocycline, and doxycycline were (ROR 5.85, 95% CI 4.96-6.91), (ROR 6.4, 95% CI 5.76-7.11), and (ROR 2.07, 95% CI 1.86-2.31), respectively. Tigecycline 54-65 receptor tyrosine kinase like orphan receptor 1 Homo sapiens 4-8 35364753-8 2022 The RORs and the 95% confidence intervals (95% CI) of tigecycline, minocycline, and doxycycline were (ROR 5.85, 95% CI 4.96-6.91), (ROR 6.4, 95% CI 5.76-7.11), and (ROR 2.07, 95% CI 1.86-2.31), respectively. Tigecycline 54-65 receptor tyrosine kinase like orphan receptor 2 Homo sapiens 165-170 35178569-11 2022 Moreover, following the ASP implementation, a dramatic reduction in tigecycline prescription by 67.3% was observed. Tigecycline 68-79 assembly factor for spindle microtubules Homo sapiens 24-27 35572689-0 2022 Emergence of a Hypervirulent Tigecycline-Resistant Klebsiella pneumoniae Strain Co-producing bla NDM-1 and bla KPC-2 With an Uncommon Sequence Type ST464 in Southwestern China. Tigecycline 29-40 NDM-1 Klebsiella pneumoniae 97-102 35572689-0 2022 Emergence of a Hypervirulent Tigecycline-Resistant Klebsiella pneumoniae Strain Co-producing bla NDM-1 and bla KPC-2 With an Uncommon Sequence Type ST464 in Southwestern China. Tigecycline 29-40 TEM beta-lactamase Klebsiella pneumoniae 107-110 35572689-0 2022 Emergence of a Hypervirulent Tigecycline-Resistant Klebsiella pneumoniae Strain Co-producing bla NDM-1 and bla KPC-2 With an Uncommon Sequence Type ST464 in Southwestern China. Tigecycline 29-40 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 111-116 35572689-1 2022 Emergence of bla NDM-1 and bla KPC-2 co-producing Klebsiella pneumoniae strains is currently attracting widespread attention, but little information is available about their tigecycline resistance, virulence, and prevalence in Southwest China. Tigecycline 174-185 TEM beta-lactamase Klebsiella pneumoniae 13-16 35572689-1 2022 Emergence of bla NDM-1 and bla KPC-2 co-producing Klebsiella pneumoniae strains is currently attracting widespread attention, but little information is available about their tigecycline resistance, virulence, and prevalence in Southwest China. Tigecycline 174-185 NDM-1 Klebsiella pneumoniae 17-22 35038616-0 2022 Evolution of tet(A) Variant Mediating Tigecycline Resistance in KPC-2-Producing Klebsiella pneumoniae during Tigecycline Treatment. Tigecycline 38-49 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 64-69 35038616-0 2022 Evolution of tet(A) Variant Mediating Tigecycline Resistance in KPC-2-Producing Klebsiella pneumoniae during Tigecycline Treatment. Tigecycline 109-120 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 64-69 35038616-1 2022 OBJECTIVES: This study investigated the underlying mechanisms of the evolution of tigecycline resistance in a patient infected with Klebsiella pneumoniae harboring blaKPC-2 during treatment. Tigecycline 82-93 KPC-2 protein Klebsiella pneumoniae 164-172 35038616-10 2022 The carbapenemase gene blaKPC-2 and a tet(A) mutation were found in the tigecycline-resistant isolate FK6768. Tigecycline 72-83 KPC-2 protein Klebsiella pneumoniae 23-31 35038616-12 2022 CONCLUSIONS: This is a report on K. pneumoniae carrying both tet(A) mutation and blaKPC-2, which led to increased tigecycline resistance in K. pneumoniae during tigecycline treatment. Tigecycline 114-125 KPC-2 protein Klebsiella pneumoniae 81-89 35038616-12 2022 CONCLUSIONS: This is a report on K. pneumoniae carrying both tet(A) mutation and blaKPC-2, which led to increased tigecycline resistance in K. pneumoniae during tigecycline treatment. Tigecycline 161-172 KPC-2 protein Klebsiella pneumoniae 81-89 35498222-5 2022 The network meta-analysis showed that ceftaroline, ceftobiprole, delafloxacin and tigecycline had similar efficacy in the indirect comparisons (Ceftaroline Odds Ratio (OR) = 1.2, 95% Crl = 0.46-3.6), ceftobiprole (OR = 1.3, 95% Crl = 0.34-3.0) and tigecycline (OR = 0.96, 95% Crl = 0.30-2.9)). Tigecycline 82-93 interleukin 31 receptor A Homo sapiens 183-186 35498222-5 2022 The network meta-analysis showed that ceftaroline, ceftobiprole, delafloxacin and tigecycline had similar efficacy in the indirect comparisons (Ceftaroline Odds Ratio (OR) = 1.2, 95% Crl = 0.46-3.6), ceftobiprole (OR = 1.3, 95% Crl = 0.34-3.0) and tigecycline (OR = 0.96, 95% Crl = 0.30-2.9)). Tigecycline 82-93 interleukin 31 receptor A Homo sapiens 228-231 35498222-5 2022 The network meta-analysis showed that ceftaroline, ceftobiprole, delafloxacin and tigecycline had similar efficacy in the indirect comparisons (Ceftaroline Odds Ratio (OR) = 1.2, 95% Crl = 0.46-3.6), ceftobiprole (OR = 1.3, 95% Crl = 0.34-3.0) and tigecycline (OR = 0.96, 95% Crl = 0.30-2.9)). Tigecycline 82-93 interleukin 31 receptor A Homo sapiens 276-279 33758948-6 2021 RESULTS: The strain P. putida ZXPA-20 resistant to meropenem and tigecycline was positive for blaVIM-2 and tmexCD1-toprJ1 genes. Tigecycline 65-76 VIM-2 Pseudomonas putida 94-102 34022417-9 2021 Susceptibility of extended-spectrum beta-lactamase (ESBL)-negative Escherichia coli to ceftaroline ranged from 67.0% in Asia/SP to 91.0% in Africa/ME; susceptibility to amikacin, meropenem and tigecycline was >=96.7% in all regions. Tigecycline 193-204 EsbL Escherichia coli 18-50 32860258-7 2020 Compared with before treatment, fibrinogen (FIB) significantly decreased after tigecycline was used while prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT) significantly increased (all P < .001). Tigecycline 79-90 fibrinogen beta chain Homo sapiens 32-42 32364269-7 2021 All AmpC and/or ESBL-phenotype E. coli were sensitive to colistin, ertapenem, imipenem, meropenem, temocillin and tigecycline, applying epidemiological cut-off values. Tigecycline 114-125 beta-lactamase Escherichia coli 4-8 33898347-7 2021 tigecycline 100 mg BID she was commenced on p.o. Tigecycline 0-11 BH3 interacting domain death agonist Homo sapiens 19-22 33361297-0 2021 IS26 mediate the acquisition of tigecycline resistance gene cluster tmexCD1-toprJ1 by IncHI1B-FIB plasmids in Klebsiella pneumoniae and Klebsie lla quasipneumoniae from food market sewage. Tigecycline 32-43 protein TnpA Klebsiella pneumoniae 0-4 33283892-12 2021 CONCLUSIONS: The proposed PPK model may serve as the basis for estimating tigecycline exposure for pharmacokinetic-pharmacodynamic analyses, and the pharmacokinetic-pharmacodynamic index and magnitude found in this study could be used for designing proper dosage regimens of tigecycline. Tigecycline 74-85 kallikrein B1 Homo sapiens 26-29 33283892-12 2021 CONCLUSIONS: The proposed PPK model may serve as the basis for estimating tigecycline exposure for pharmacokinetic-pharmacodynamic analyses, and the pharmacokinetic-pharmacodynamic index and magnitude found in this study could be used for designing proper dosage regimens of tigecycline. Tigecycline 275-286 kallikrein B1 Homo sapiens 26-29 32860258-7 2020 Compared with before treatment, fibrinogen (FIB) significantly decreased after tigecycline was used while prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT) significantly increased (all P < .001). Tigecycline 79-90 fibrinogen beta chain Homo sapiens 44-47 33222688-9 2020 Tigecycline showed a bactericidal effect at 48 h that achieved a reduction of > 4log10 CFU/mL against the intracellular mycobacteria, while imipenem showed a bacteriostatic effect. Tigecycline 0-11 thrombopoietin Mus musculus 91-93 32355990-6 2020 Hypofibrinogenaemia developed at a median of 6 (4-8) days after tigecycline treatment, and the fibrinogen level returned to normal at a median of 3 (3-5) days after tigecycline discontinuation. Tigecycline 64-75 fibrinogen beta chain Homo sapiens 4-14 32765433-7 2020 Mortality rate is high in HMP infected with CR-Enterobacteriaceae, more particularly in case of acute myeloid leukemia and unresolved neutropenia, due to inappropriate empiric management and delayed administration of targeted antibiotics, such as tigecycline, colistin, or new associations of active drugs. Tigecycline 247-258 inner membrane mitochondrial protein Homo sapiens 26-29 32294173-9 2020 RESULTS: Inhaled tigecycline proved highly effective against M. abscessus in GM-CSF knockout mice. Tigecycline 17-28 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 77-83 33228012-1 2020 BACKGROUND: Tigecycline is a therapeutic option for carbapenemase-producing Klebsiella pneumoniae (CP-Kp). Tigecycline 12-23 phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha Homo sapiens 99-104 33228012-13 2020 CONCLUSION: Tigecycline monotherapy was as efficacious as other antimicrobials in the treatment of bloodstream infections due to CP-Kp isolates with a tigecycline"s MIC <= 0.5 mg/L. Tigecycline 12-23 phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha Homo sapiens 129-134 33228012-13 2020 CONCLUSION: Tigecycline monotherapy was as efficacious as other antimicrobials in the treatment of bloodstream infections due to CP-Kp isolates with a tigecycline"s MIC <= 0.5 mg/L. Tigecycline 151-162 phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha Homo sapiens 129-134 33120753-5 2020 The decrease in fibrinogen occurred within 3 to 7 days of tigecycline treatment. Tigecycline 58-69 fibrinogen beta chain Homo sapiens 16-26 33120753-9 2020 OUTCOMES: The fibrinogen level normalized within 5 days after the withdrawal of tigecycline. Tigecycline 80-91 fibrinogen beta chain Homo sapiens 14-24 33149937-4 2020 Chitosan/tigecycline (CS/TGC) antibacterial biofilm was prepared by coating CS/TGC nanoparticles on mammalian-derived ECM. Tigecycline 9-20 citrate synthase Homo sapiens 22-24 33149937-4 2020 Chitosan/tigecycline (CS/TGC) antibacterial biofilm was prepared by coating CS/TGC nanoparticles on mammalian-derived ECM. Tigecycline 9-20 citrate synthase Homo sapiens 76-78 32355990-7 2020 In the multivariate analysis, intra-abdominal infection (p = 0.005), fibrinogen level at tigecycline initiation (p < 0.001), maintenance dose (p = 0.039), and treatment duration (p = 0.002) were found to be related to hypofibrinogenaemia. Tigecycline 89-100 fibrinogen beta chain Homo sapiens 69-79 32355990-9 2020 CONCLUSION: Tigecycline-associated hypofibrinogenaemia often developed on the 6th (4th-8th) day of tigecycline use and was associated with intra-abdominal infection, fibrinogen level at tigecycline initiation, maintenance dose, and treatment duration of tigecycline but not cefoperazone/sulbactam. Tigecycline 12-23 fibrinogen beta chain Homo sapiens 39-49 32355990-9 2020 CONCLUSION: Tigecycline-associated hypofibrinogenaemia often developed on the 6th (4th-8th) day of tigecycline use and was associated with intra-abdominal infection, fibrinogen level at tigecycline initiation, maintenance dose, and treatment duration of tigecycline but not cefoperazone/sulbactam. Tigecycline 99-110 fibrinogen beta chain Homo sapiens 39-49 32355990-9 2020 CONCLUSION: Tigecycline-associated hypofibrinogenaemia often developed on the 6th (4th-8th) day of tigecycline use and was associated with intra-abdominal infection, fibrinogen level at tigecycline initiation, maintenance dose, and treatment duration of tigecycline but not cefoperazone/sulbactam. Tigecycline 186-197 fibrinogen beta chain Homo sapiens 39-49 32355990-9 2020 CONCLUSION: Tigecycline-associated hypofibrinogenaemia often developed on the 6th (4th-8th) day of tigecycline use and was associated with intra-abdominal infection, fibrinogen level at tigecycline initiation, maintenance dose, and treatment duration of tigecycline but not cefoperazone/sulbactam. Tigecycline 186-197 fibrinogen beta chain Homo sapiens 39-49 31408445-11 2019 Moreover, three ESBL-producing K. pneumoniae ST11 strains which were resistant to carbapenems carried the blaNDM-1 and blaKPC-2, two of which also bearing blaOXA-48 were resistant to all antibiotics (including Tigecycline). Tigecycline 210-221 EsbL Escherichia coli 16-20 32570218-9 2020 Interestingly, the mitochondrial energy inhibitor, tigecycline, combined with Adriamycin reversed the cellular resistance caused by Sirt1 overexpression in vivo. Tigecycline 51-62 sirtuin 1 Mus musculus 132-137 32345737-4 2020 In this study, the phenotypes and genotypes of all the tet(X)-positive tigecycline-resistant strains isolated from a slaughterhouse in China were characterized by antimicrobial susceptibility testing, conjugation, pulsed-field gel electrophoresis with S1 nuclease (S1-PFGE), and PCR. Tigecycline 71-82 sulfatase modifying factor 2 Homo sapiens 268-272 32322504-0 2020 Carbapenemase-producing Klebsiella pneumoniae intra-abdominal infection successfully treated with ceftazidime/avibactam plus tigecycline. Tigecycline 125-136 OXA-48 Klebsiella pneumoniae 0-13 32141702-0 2020 Antibiotic tigecycline inhibits cell proliferation, migration and invasion via down-regulating CCNE2 in pancreatic ductal adenocarcinoma. Tigecycline 11-22 cyclin E2 Homo sapiens 95-100 32141702-12 2020 Interestingly, we found CCNE2 expression was declined distinctly after tigecycline treatment. Tigecycline 71-82 cyclin E2 Homo sapiens 24-29 32141702-13 2020 Then, CCNE2 was overexpressed to rescue tigecycline-induced effect. Tigecycline 40-51 cyclin E2 Homo sapiens 6-11 32141702-14 2020 The results showed that CCNE2 overexpression significantly rescued tigecycline-inhibited cell proliferation and migration/invasion. Tigecycline 67-78 cyclin E2 Homo sapiens 24-29 32141702-15 2020 Collectively, we showed that tigecycline inhibits cell proliferation, migration and invasion via down-regulating CCNE2, and tigecycline might be used as a potential drug for PDAC treatment alone or combined with gemcitabine. Tigecycline 29-40 cyclin E2 Homo sapiens 113-118 31969868-2 2019 The aim of this study was to investigate combinatorial pharmacodynamics of colistin and tigecycline against E. coli harboring bla NDM- 5 and mcr-1, with possible mechanisms explored as well. Tigecycline 88-99 beta-lactamase Escherichia coli 126-129 31969868-7 2019 These data suggest that the use of colistin and tigecycline combination can provide a therapeutic alternative for infection caused by multidrug-resistant E. coli that harbored both bla NDM- 5 and mcr-1. Tigecycline 48-59 beta-lactamase Escherichia coli 181-184 31713108-9 2019 Tigecycline-induced coagulopathy usually manifests as the dose-dependent prolongation of prothrombin time and activated partial thromboplastin time and a reduction in the fibrinogen level. Tigecycline 0-11 fibrinogen beta chain Homo sapiens 171-181 31430857-4 2019 Here we show that tetracycline analogs, especially tigecycline and minocycline, inhibit osteoclast formation by blocking MMP-9-mediated histone H3 tail cleavage. Tigecycline 51-62 matrix metallopeptidase 9 Danio rerio 121-126 31430857-5 2019 Our molecular docking approach found that tigecycline and minocycline are the most potent inhibitors of MMP-9. Tigecycline 42-53 matrix metallopeptidase 9 Danio rerio 104-109 31118131-8 2019 We finally show that specific inhibition of mitochondrial translation via EF-Tu depletion produces the similar anti-osteosarcoma effects of tigecycline. Tigecycline 140-151 Tu translation elongation factor, mitochondrial Mus musculus 74-79 31426870-18 2019 Tigecycline was stopped, but the hypoglycemia resolved only after a further 34 h. The insulin and C-peptide levels were found to be markedly elevated during the hypoglycemia. Tigecycline 0-11 insulin Homo sapiens 86-93 31505641-9 2019 MRSA were most susceptible to ceftobiprole, linezolid and telavancin (100%), daptomycin (99.9%), vancomycin (99.8%) and tigecycline (99.2%). Tigecycline 120-131 solute carrier family 9 member A6 Homo sapiens 0-4 31505647-5 2019 RESULTS: The annual proportion of isolates of E. coli that were ESBL producing increased from 3.4% in 2007 to 11.1% in 2016 (P < 0.0001); >95% of ESBL-producing E. coli were susceptible to amikacin, colistin, ertapenem, meropenem and tigecycline. Tigecycline 240-251 EsbL Escherichia coli 64-68 31260434-10 2019 Polymyxins are useful in the treatment of patients infected with Klebsiella pneumoniae NDM (New Delhi metallo-beta-lactamase), where the effectiveness of therapy is greater when colistin is used together with carbapenem or rifampicin or tigecycline. Tigecycline 237-248 NDM-1 Klebsiella pneumoniae 92-124 31056648-2 2019 Based on our previous data showing that doxycycline and minocycline work as the positive allosteric modulator (PAM) of PAC1-R, we used computer molecular docking and isothermal titration calorimetry assay to further determine the bindings of doxycycline/minocycline"s derivatives including tetracycline/tigecycline with the N-terminal extracellular domain of PAC1-R (PAC1-EC1). Tigecycline 303-314 ADCYAP receptor type I Homo sapiens 119-125 31056648-2 2019 Based on our previous data showing that doxycycline and minocycline work as the positive allosteric modulator (PAM) of PAC1-R, we used computer molecular docking and isothermal titration calorimetry assay to further determine the bindings of doxycycline/minocycline"s derivatives including tetracycline/tigecycline with the N-terminal extracellular domain of PAC1-R (PAC1-EC1). Tigecycline 303-314 ADCYAP receptor type I Homo sapiens 119-123 31056648-4 2019 The results showed that tetracycline/tigecycline had significant lower affinity to PAC1-EC1 than doxycycline/minocycline, which was consistent with their non-positive allosteric modulation activity on PAC1-R. Tigecycline 37-48 ADCYAP receptor type I Homo sapiens 83-87 31056648-4 2019 The results showed that tetracycline/tigecycline had significant lower affinity to PAC1-EC1 than doxycycline/minocycline, which was consistent with their non-positive allosteric modulation activity on PAC1-R. Tigecycline 37-48 Susceptibility to lysis by alloreactive natural killer cells Homo sapiens 88-91 31056648-4 2019 The results showed that tetracycline/tigecycline had significant lower affinity to PAC1-EC1 than doxycycline/minocycline, which was consistent with their non-positive allosteric modulation activity on PAC1-R. Tigecycline 37-48 ADCYAP receptor type I Homo sapiens 201-207 30247801-4 2018 Mechanism analysis found that tigecycline led to cell cycle arrest at G0/G1 with down-regulation of p21, CDK2 and cyclin D1, rather than induced apoptosis, in MM cells. Tigecycline 30-41 cyclin dependent kinase inhibitor 1A Homo sapiens 100-103 30591219-5 2019 Mechanistically, tigecycline specifically inhibits translation by mitochondrial ribosome but not nuclear or cytosolic ribosome, leading to mitochondrial dysfunction, oxidative stress and damage, AMPK activation and inhibition of mTOR signaling in ovarian cancer cells. Tigecycline 17-28 protein kinase AMP-activated catalytic subunit alpha 1 Homo sapiens 195-199 30591219-5 2019 Mechanistically, tigecycline specifically inhibits translation by mitochondrial ribosome but not nuclear or cytosolic ribosome, leading to mitochondrial dysfunction, oxidative stress and damage, AMPK activation and inhibition of mTOR signaling in ovarian cancer cells. Tigecycline 17-28 mechanistic target of rapamycin kinase Homo sapiens 229-233 30828002-5 2019 What we found was that the plasma fibrinogen (FIB) level was 4.63 +- 1.56 g/L before tigecycline treatment, and decreased to 2.92 +- 1.23 g/L during treatment, which was statistically significant (p < 0.001). Tigecycline 85-96 fibrinogen beta chain Homo sapiens 34-44 30828002-5 2019 What we found was that the plasma fibrinogen (FIB) level was 4.63 +- 1.56 g/L before tigecycline treatment, and decreased to 2.92 +- 1.23 g/L during treatment, which was statistically significant (p < 0.001). Tigecycline 85-96 fibrinogen beta chain Homo sapiens 46-49 30828002-7 2019 This study demonstrates that treatment of tigecycline could reduce FIB, prolong aPTT and PT. Tigecycline 42-53 fibrinogen beta chain Homo sapiens 67-70 31259704-7 2018 In splenocyte cultures, tigecycline suppressed splenocyte proliferation with IC50 3-5 mmol L-1, significantly increased IL-2 secretion and reduced IL-17 secretion in a dose dependent mode. Tigecycline 24-35 interleukin 2 Mus musculus 120-124 31259704-7 2018 In splenocyte cultures, tigecycline suppressed splenocyte proliferation with IC50 3-5 mmol L-1, significantly increased IL-2 secretion and reduced IL-17 secretion in a dose dependent mode. Tigecycline 24-35 interleukin 17A Mus musculus 147-152 30351265-0 2018 A mutation in anti-sigma factor MAB_3542c may be responsible for tigecycline resistance in Mycobacterium abscessus. Tigecycline 65-76 MAB_3542c Mycobacterium abscessus 32-41 30351265-6 2018 The MAB_3542c mutation may represent a novel determinant of tigecycline resistance. Tigecycline 60-71 MAB_3542c Mycobacterium abscessus 4-13 32040455-10 2019 were ESBL producers, susceptible to tigecycline. Tigecycline 36-47 EsbL Escherichia coli 5-9 31168197-6 2018 Using the EUCAST criteria, the rate of resistance to tigecycline for the OXA-23 MBL-positive, OXA-23 MBL-negative and carbapenemase-negative strains for BMM was 54.5% (6/11), 29.4% (5/17) and 2.7% (1/37), respectively; the OXA-24/40 and OXA-58 producing organisms did not exhibit any resistance. Tigecycline 53-64 class D beta-lactamase OXA-23 Acinetobacter baumannii 73-79 31168197-6 2018 Using the EUCAST criteria, the rate of resistance to tigecycline for the OXA-23 MBL-positive, OXA-23 MBL-negative and carbapenemase-negative strains for BMM was 54.5% (6/11), 29.4% (5/17) and 2.7% (1/37), respectively; the OXA-24/40 and OXA-58 producing organisms did not exhibit any resistance. Tigecycline 53-64 class D beta-lactamase OXA-23 Acinetobacter baumannii 94-100 30247801-4 2018 Mechanism analysis found that tigecycline led to cell cycle arrest at G0/G1 with down-regulation of p21, CDK2 and cyclin D1, rather than induced apoptosis, in MM cells. Tigecycline 30-41 cyclin dependent kinase 2 Homo sapiens 105-109 30247801-4 2018 Mechanism analysis found that tigecycline led to cell cycle arrest at G0/G1 with down-regulation of p21, CDK2 and cyclin D1, rather than induced apoptosis, in MM cells. Tigecycline 30-41 cyclin D1 Homo sapiens 114-123 30247801-6 2018 Mechanisms modulating autophagy found that tigecycline enhanced the phosphorylation of AMPK, but did not decrease the phosphorylation of Akt, to inhibit the phosphorylation of mTOR and its two downstream effectors p70S6K1 and 4E-BP1. Tigecycline 43-54 protein kinase AMP-activated catalytic subunit alpha 1 Homo sapiens 87-91 30247801-6 2018 Mechanisms modulating autophagy found that tigecycline enhanced the phosphorylation of AMPK, but did not decrease the phosphorylation of Akt, to inhibit the phosphorylation of mTOR and its two downstream effectors p70S6K1 and 4E-BP1. Tigecycline 43-54 mechanistic target of rapamycin kinase Homo sapiens 176-180 30605291-0 2018 Effect of tigecycline on the production of selected cytokines and counts of murine CD4+ and CD8+ T cells - an in vitro study. Tigecycline 10-21 CD4 antigen Mus musculus 83-86 30584308-9 2018 Nausea, drug ineffectiveness, postoperative wound infection, vomiting, and pyrexia were the most common adverse events in tigecycline-treated subjects; pyrexia, nausea, vomiting, and increased alanine aminotransferase and aspartate aminotransferase levels were most common in imipenem/cilastatin-treated subjects; none were unanticipated. Tigecycline 122-133 glutamic--pyruvic transaminase Homo sapiens 193-217 30605291-1 2018 Due to the unrecognized effect of tigecycline (TIG) on CD4+ and CD8+ T cells, the present study has been undertaken in order to determine whether the drug can affect these cells in respect of their counts, and the production of IFN-gamma, IL-17 (pro-inflammatory and immune-protective cytokines), IL-4 (anti-inflammatory and immune-protective cytokine), IL-10 and TGF-beta (anti-inflammatory and immune-suppressive cytokines). Tigecycline 34-45 CD4 antigen Mus musculus 55-58 30605291-1 2018 Due to the unrecognized effect of tigecycline (TIG) on CD4+ and CD8+ T cells, the present study has been undertaken in order to determine whether the drug can affect these cells in respect of their counts, and the production of IFN-gamma, IL-17 (pro-inflammatory and immune-protective cytokines), IL-4 (anti-inflammatory and immune-protective cytokine), IL-10 and TGF-beta (anti-inflammatory and immune-suppressive cytokines). Tigecycline 47-50 CD4 antigen Mus musculus 55-58 30076847-9 2018 However, reduced bacterial richness was correlated with increased expression of TLR2 and TLR9 in antibiotic-treated groups and TLR6 was also up-regulated by the immunomodulatory tetracyclines with higher efficacy (doxycycline, minocycline and tigecycline). Tigecycline 243-254 toll-like receptor 6 Mus musculus 127-131 30587490-8 2018 Although collistin showed 0% resistant while ceftriaxone, ciprofloxacin, gentamicin, and tigecycline showed 90%, 68%, 66%, 66% and 62% resistance against Acinetobacter spp. Tigecycline 89-100 histocompatibility minor 13 Homo sapiens 168-171 30068997-5 2018 This study identified 67 eravacycline-nonsusceptible isolates; among the extended-spectrum beta-lactamase (ESBL)-positive isolates, eravacycline-nonsusceptible isolates were detected more frequently than tigecycline-nonsusceptible isolates (21.7% vs. 9.4%, p = 0.001). Tigecycline 204-215 CTX-M-15 Klebsiella pneumoniae 73-105 29950204-12 2018 The high dose tigecycline can decrease the temperature, calcitonin and C-reactive protein levels, and can control infection without the hepatic and renal impairment, but it needs to be confimed by more prospective studies. Tigecycline 14-25 C-reactive protein Homo sapiens 71-89 29565228-1 2018 The aim of this prospective, randomized study was to compare the effects of tigecycline and imipenem-cilastatin on fibrinogen levels in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Tigecycline 76-87 fibrinogen beta chain Homo sapiens 115-125 29565228-6 2018 In conclusion, compared to imipenem-cilastatin, tigecycline was associated with a significant decrease in fibrinogen levels, following CRS and HIPEC. Tigecycline 48-59 fibrinogen beta chain Homo sapiens 106-116 29307862-13 2018 Isolates with a tigecycline MIC of 16mg/L also showed overexpression of rarA compared with TIG-susceptible isolates. Tigecycline 16-27 retinoic acid receptor alpha Homo sapiens 72-76 28069382-5 2017 Mechanistically, tigecycline specifically inhibits mitochondrial translation as shown by the decreased protein levels of Cox-1 and -2 but not Cox-4 or Grp78, and increased mRNA levels of Cox-1 and -2 but not Cox-4 in HCC cells exposed to tigecycline. Tigecycline 17-28 mitochondrially encoded cytochrome c oxidase I Homo sapiens 121-133 29411661-4 2018 Few antibiotics are currently available when such MDR Gram-negatives are encountered and older agents such as polymyxin B, colistin (polymyxin E), and tigecycline have typically performed poorly in HABP/VABP. Tigecycline 151-162 hyaluronan binding protein 2 Homo sapiens 198-202 29031650-5 2018 Tigecycline (50mg BID, mainly in combination (69.4%), mean duration of 58 days) was indicated for multidrug resistance (90.6%) and/or previous antibiotic intolerance (36.1%), and/or as second- or third-line therapy (69.4%). Tigecycline 0-11 BH3 interacting domain death agonist Homo sapiens 18-21 29386360-4 2018 BCL2 activation in mouse Emu-myc lymphomas antagonized tigecycline-induced cell death, which was specifically restored by combined treatment with the BCL2 inhibitor venetoclax. Tigecycline 55-66 B cell leukemia/lymphoma 2 Mus musculus 150-154 29386360-5 2018 In line with these findings, tigecycline and two related antibiotics, tetracycline and doxycycline, synergized with venetoclax in killing human MYC/BCL2 DHL cells. Tigecycline 29-40 MYC proto-oncogene, bHLH transcription factor Homo sapiens 144-147 29386360-5 2018 In line with these findings, tigecycline and two related antibiotics, tetracycline and doxycycline, synergized with venetoclax in killing human MYC/BCL2 DHL cells. Tigecycline 29-40 BCL2 apoptosis regulator Homo sapiens 148-152 29312795-4 2017 Compared to normal hematopoietic cells, tigecycline is more active against primary lymphocytes and CD34 progenitors from ALL patients through decreasing survival and clonogenic growth. Tigecycline 40-51 CD34 molecule Homo sapiens 99-103 29386360-0 2018 Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 double-hit B cell lymphoma. Tigecycline 28-39 myelocytomatosis oncogene Mus musculus 81-84 29386360-0 2018 Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 double-hit B cell lymphoma. Tigecycline 28-39 B cell leukemia/lymphoma 2 Mus musculus 85-89 29386360-2 2018 MYC activation sensitizes cells to inhibition of mitochondrial translation by the antibiotic tigecycline, and treatment with this compound provides a therapeutic window in a mouse model of MYC-driven lymphoma. Tigecycline 93-104 myelocytomatosis oncogene Mus musculus 0-3 29386360-4 2018 BCL2 activation in mouse Emu-myc lymphomas antagonized tigecycline-induced cell death, which was specifically restored by combined treatment with the BCL2 inhibitor venetoclax. Tigecycline 55-66 B cell leukemia/lymphoma 2 Mus musculus 0-4 29386360-4 2018 BCL2 activation in mouse Emu-myc lymphomas antagonized tigecycline-induced cell death, which was specifically restored by combined treatment with the BCL2 inhibitor venetoclax. Tigecycline 55-66 myelocytomatosis oncogene Mus musculus 29-32 29404396-2 2018 By simultaneously disrupting mitochondrial respiration and inhibiting BCR-ABL kinase activity using the antibiotic tigecycline and imatinib respectively, we effectively eradicated LSCs and prevented disease relapse in pre-clinical animal models. Tigecycline 115-126 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 70-77 29101083-0 2017 Draft genome sequence of a tigecycline-resistant KPC-2-producing Klebsiella pneumoniae ST15 clinical isolate from China. Tigecycline 27-38 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 49-54 29101083-3 2017 Here we report the draft genome sequence of a clinical tigecycline-resistant KPC-2-producing K. pneumoniae isolate (TRKP1). Tigecycline 55-66 carbapenem-hydrolyzing beta-lactamase KPC-2 Klebsiella pneumoniae 77-82 28645610-8 2017 Importantly, genetic inhibition of mitochondrial translation by EF-Tu knockdown reproduced the inhibitory effects of tigecycline. Tigecycline 117-128 Tu translation elongation factor, mitochondrial Homo sapiens 64-69 28069382-5 2017 Mechanistically, tigecycline specifically inhibits mitochondrial translation as shown by the decreased protein levels of Cox-1 and -2 but not Cox-4 or Grp78, and increased mRNA levels of Cox-1 and -2 but not Cox-4 in HCC cells exposed to tigecycline. Tigecycline 17-28 cytochrome c oxidase subunit 4I1 Homo sapiens 142-147 28069382-5 2017 Mechanistically, tigecycline specifically inhibits mitochondrial translation as shown by the decreased protein levels of Cox-1 and -2 but not Cox-4 or Grp78, and increased mRNA levels of Cox-1 and -2 but not Cox-4 in HCC cells exposed to tigecycline. Tigecycline 17-28 heat shock protein family A (Hsp70) member 5 Homo sapiens 151-156 28069382-5 2017 Mechanistically, tigecycline specifically inhibits mitochondrial translation as shown by the decreased protein levels of Cox-1 and -2 but not Cox-4 or Grp78, and increased mRNA levels of Cox-1 and -2 but not Cox-4 in HCC cells exposed to tigecycline. Tigecycline 17-28 mitochondrially encoded cytochrome c oxidase I Homo sapiens 187-199 28069382-9 2017 Importantly, antioxidant N-acetyl-l-cysteine (NAC) reverses the effects of tigecycline, suggesting that oxidative stress is required for the action of tigecycline in HCC cells. Tigecycline 75-86 X-linked Kx blood group Homo sapiens 46-49 28069382-9 2017 Importantly, antioxidant N-acetyl-l-cysteine (NAC) reverses the effects of tigecycline, suggesting that oxidative stress is required for the action of tigecycline in HCC cells. Tigecycline 151-162 X-linked Kx blood group Homo sapiens 46-49 27571409-7 2016 Additionally, a screen of US Food and Drug Administration-approved (FDA-approved) drugs identified the MPT antagonist tigecycline (TIG) as a potent inhibitor of Rb/p53-deficient tumor cell proliferation. Tigecycline 118-129 transformation related protein 53 Mus musculus 164-167 28081345-0 2016 Growing OXA-23 type strains among carbapenem-resistant Acinetobacter baumannii and tigecycline as an alternate combination therapy. Tigecycline 83-94 class D beta-lactamase OXA-23 Acinetobacter baumannii 8-14 26692183-0 2016 Emergence of tigecycline- and carbapenem-nonsusceptible Klebsiella pneumoniae ST11 clone in patients without exposure to tigecycline. Tigecycline 13-24 Pancreatic endocrine tumor suppressor Homo sapiens 78-82 26692183-0 2016 Emergence of tigecycline- and carbapenem-nonsusceptible Klebsiella pneumoniae ST11 clone in patients without exposure to tigecycline. Tigecycline 121-132 Pancreatic endocrine tumor suppressor Homo sapiens 78-82 27635472-5 2016 Inhibition of mitochondrial translation with the antibiotic Tigecycline was synthetic-lethal with Myc activation, impaired respiratory activity and tumor cell survival in vitro, and significantly extended lifespan in lymphoma-bearing mice. Tigecycline 60-71 myelocytomatosis oncogene Mus musculus 98-101 27571409-7 2016 Additionally, a screen of US Food and Drug Administration-approved (FDA-approved) drugs identified the MPT antagonist tigecycline (TIG) as a potent inhibitor of Rb/p53-deficient tumor cell proliferation. Tigecycline 131-134 transformation related protein 53 Mus musculus 164-167